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Abstract
Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged as a very promising
approach to combating cancer. Despite its ability to eliminate tumors shown in some clinical trials, CAR-T cell therapy
involves some significant safety challenges, such as cytokine release syndrome (CRS) and “on-target, off-tumor” toxicity,
which is related to poor control of the dose, location, and timing of T cell activity. In the past few years, some
strategies to avoid the side effects of CAR-T cell therapy have been reported, including suicide gene, inhibitory CAR,
dual-antigen receptor, and the use of exogenous molecules as switches to control the CAR-T cell functions. Because of
the advances of the CAR paradigm and other forms of cancer immunotherapy, the most effective means of defeating
the cancer has become the integration therapy with the combinatorial control system of switchable dual-receptor
CAR-T cell and immune checkpoint blockade.
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Background
A specific type of immune therapy, known as a green
therapy, has emerged as an exciting new approach for
cancer therapy, especially the adoptive cells transfer
(ACT) therapy [1–3]. Unlike surgery, radiotherapy, and
chemotherapy, the cell-based therapy can facilitate accur-
ate decisions and execute highly complex behaviors [4–6].
The autologous lymphocytes isolated from a patient’s own
peripheral blood are endowed with the ability of tumor
antigen specificity and rendered capable of eliminating
cancer cells expanded ex vivo, and then reinfused into the
patient to attack any malignant tumor [7–10]. The majo-
rity of preclinical and clinical data regarding autologous T
cells have highlighted the safety of using the cell therapy
and the lack of potential for graft-versus-host disease
(GvHD) mediated by the allogeneic T cells [11–13]. The T
cell receptor (TCR), an α/β heterodimer, has the ability to
redirect the tumor antigens in a major histocompatibility-
complex-dependent (MHC) manner [14–16]. The con-
ventional T cells are activated upon TCR combining with
other cell surface molecules, termed TCR/CD3 complex,
which contains 10 immunoreceptor tyrosine activation
motifs (ITAMs) and 20 tyrosine-phosphorylation sites
[17–19]. The tumor escape mechanism, however, is asso-
ciated with the downregulation of the MHC molecule on
the surface of the tumor cell, which restrains the homing
of T cells because the interaction between T cell receptor
and peptide-MHC is a prerequisite for T cell activation
[20–22]. In contrast, the structure and signaling pathway
of the chimeric antigen receptor (CAR) are delicate. CARs
permanently endow the patient-derived T cells with the
ability to recognize and kill any tumor cells expressing the
antigens without MHC molecules, and render the tumor
cell “visible” to T cell immune surveillance [23–25]. Re-
cent advances in genetic engineering and improved recog-
nition of T cells have resulted in the design of new
receptor mechanisms, termed CARs. Human T cells
modified with this synthetic receptor can specifically redir-
ect tumor antigens and undertake the striking efficacy for
many human malignancies [26–28].
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Like that of the conventional T cell, the structure of
CAR-modified T cell contains three moieties, i.e., an
extracellular domain, single-chain antibody fragments
(scFv), that recognize and bind a specific tumor antigen
independent of MHC molecule, a transmembrane domain
that usually comprises the homodimer of CD3 or CD8
molecule, and an intracellular signaling domain including
a signal-transduction component of the T-cell receptor
(e.g., CD3ζ or FcεRIγ) and a costimulatory receptor (e.g.,
4-1BB, CD28, or OX40) (Fig. 1) [29–32]. The initial CAR-
T cell comprises the scFv element and the CD3ζ signaling
domain, which endows the T cell with the abilities of
homing and activation (Fig. 1b). However, the cytotoxicity
of first-generation CAR-T cells is transient in vivo. To
enhance the durability of CAR-T cell cytotoxicity, the
second- and third-generation CAR were developed by
addition of single and dual costimulatory signaling
domains respectively (Fig. 1c, d) [33, 34]. During the last
decade, CAR-T cells have shown impressive results in
patients with hematological tumor, but have limitations in
treating solid tumors probably due to the blunt immune-
surveillance that the immune suppressor cells, cytokines,
and some proteins hinder T cell functions in tumor
microenvironment [35–39]. To overcome this weak-
ness, Koneru et al. recently developed a new module
of CAR-T cells simultaneously transduced with both
CAR and IL-12 genes, known as armored CAR-T
cells, which can penetrate the ovarian tumor site with
surmounting the tumor microenvironment [40–42].
Some researchers have also demonstrated that the re-
lease of specific enzymes by T cells, known as heparanase
(HPSE), which can help immunocytes pass through
physical barriers with degradation of extracellular matrix
(ECM) that possesses an ability to prevent the T cells hom-
ing to tumor site. Some chemokine receptors have also
been introduced into CAR-T cell, which can drive effective
T cell infiltration into the tumor bed (Fig. 1e) [43–45].
Despite the promising clinical results, CAR-T cell
therapy also involves several deleterious types of toxicity
due to the inability to control T cell activity and some
tumor-associated antigens that are presented by both
diseased and healthy tissue. The prominent toxicity of
CAR-T cell therapy involves cytokine release syndrome
(CRS) and “on-target, off-tumor” toxicity [46–49]. The
CRS effect, so-called cytokine-associated toxicity, is a
result of intense tumor-killing responses mediated by
large numbers of activated lymphocytes (B cells, T cells,
and natural killer cells) [50]. According to a previous
clinical trial, NCT0265014, the levels of several cytokines
including interleukin 6 (IL-6) and interferon γ (IFN-γ)
are markedly elevated in patient serum after receiving
genetically engineered T cells. At the early stage of
CAR-T cell therapy, large numbers of CAR-T cells are
reinfused into patients with refractory and relapse
malignancies. This results in rapid elimination of tumor
cell and extends the patient survival considerably [51, 52].
Concomitantly, the obtained cytokine levels on patients
with the administration of adoptive T-cell therapy are sev-
eral hundred times higher than the baseline level, which
typically causes a clinical syndrome including fever,
hypotension, and neurological changes, potentially leading
to rapid death [53, 54]. Lee et al. published a grading
system for assessing the severity of CRS. In this system,
the CRS has five grades based on the clinical signs and
symptoms [55]. As conventional adverse effects derived
from drugs, CRS toxicity can be controlled by reducing
the dosage of the active T cells. However, the numbers of
T cell are difficult to control and may eventually exceed a
threshold, resulting in some severe side responses. In
addition to CRS, the second safety concern associated
with the CAR-T cell therapy is a normal tissue damage
attributable to the presence of the tumor antigens on the
peritumoral tissues [56, 57]. In current reports, tumor
antigens that are expressed on cancer cells but not on
normal cells are rare, especially for solid tumors [58]. In
this way, tumor-associated antigens are often currently
used as targeting molecules for CARs. The lethal toxicity
described as “on-target, off-tumor” effect, to date, has
been reported in some cancer immunotherapy clinical tri-
als covering the infusion of engineered-T cells. For in-
stance, the most successful therapy for targeting the B-cell
malignancies has been reported after infusion of CAR-T
cell with specificity to CD19 in an ongoing clinical trial
NCT00924326. Owing to the targeting and eradication of
normal B cells, long-term B-cell aplasia symptoms appear
in patients with autologous T cell expressing the second-
generation CAR with CD19 scFv [59]. This off-tumor
expression of the interesting target molecule in normal
cell leads to rapid cardiopulmonary toxicity [60]. For an-
other case, a patient with the metastatic renal cell carcin-
oma expressing carboxyanhydrase-IX (CAIX) obtains the
common toxicity criteria (CTC) grade 2–4 liver enzyme
disturbances after receiving the CAR-modified T cell
against CAIX antigen [61]. All of these types of on-target
toxicity generally stem from the inability of CAR-T cell to
distinguish between normal cell and cancer cell.
During the past few years, many modulations of the
CAR-T cell have been developed and proved to be effect-
ive and safe [62–64]. In this review, the characteristics of
these new technologies are summarized and analyzed.
Based on previous research into technology to improve
the safety of CAR-T cells (Fig. 2), the autonomous
control (e.g., homing and specific recognition of the
CAR-T cell) is the first-choice way of ameliorating T cell
security. This involves autocrine cytokines against the
tumor immunosuppressive microenvironment and the
multireceptor presented on the T cells surface that
specifically reject the cancer tissue with some tumor
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associated antigens. Later, some synthetic control devices
that can alter the CAR-T cell activity can be implemented
in some studies combined with exogenous molecules,
which can produce “smart T cell” whose therapeutic func-
tions are precisely controlled over the timing and dosage,
thereby alleviating toxicity. These strategies offer specific
Fig. 1 Schematic diagram of TCR- and CAR-modified T cells in adoptive T cells therapy. a Activation, proliferation, and cytotoxicity of the T cell
are dependent upon the dual signal pathway that includes the T cell receptors (TCRs) that recognize peptide antigens which were processed by
the antigen-presenting cells and presented upon the major histocompatibility complex (MHC) of a target cells, and the costimulatory receptor of
T cell simultaneously engages a ligand, such as CD28 and B7 molecules. b The first-generation CAR contains only the antigen recognition signal,
CD3ζ domain, resulting in the transient activation and proliferation of the CAR-T cell based on scFv specificity. c–d The second- and third-generation
CARs contain one and two additional costimulatory signaling domains, respectively, such as CD28, CD137 (4-1BB), and CD134 (OX40).
The costimulatory signaling domains can facilitate greater proliferation of modified-T cell and greater cytotoxicity than first-generation
CAR. e To significantly enhance the overall cytotoxicity of the modified-T cell, the fourth-generation CAR-T cell is generally modified to
express CARs with an inducible cytokine genes, such as IL-12 or heparinase, which can stimulate T cell to reach the surface of tumor
cells in degrading the extracellular matrix (ECM) within the tumor microenvironment and blocking the inhibitory signaling pathway. f The
next-generation structure of the CARs with effective specificity for target cells lacking several side effects to the body will be generated
in the near future, including reconstruction of endogenous structure and introduction of exogenous regulatory
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advantages, and the combinatorial strategy involving the
dual-receptor T cell and a dependent-molecule may
become increasingly viable. In this system, the effective
CAR-T cells can target the cancer cell attributed to the
receptor with a specificity for the tumor antigen, and then
be activated over the exogenous molecules targeting the
other receptor (Fig. 3). Additionally, the receptor recogni-
tion domain of controlled molecules was coupled to
another molecule carrying antitumor activity as a way to
achieve higher cytotoxicity.
Fig. 2 Building strategies to improve the safety of CAR-modified T cells therapy. For upper left, when the release of cytokines by CAR-T cells after
killing tumor cells becomes more pronounced than at basic levels, such as interleukin-2 (IL-2) and interferon-γ (IFN-γ), the inducible
caspase 9 (iCasp9) can be dimerized, which usually leads to the rapid apoptosis of T cells expressing the iCasp9 suicide gene by addition
of a synthetic dimerizing drug AP1903. For upper middle, to achieve the precise regulation of the CAR-T cells, the inhibitory strategy
usually harnesses an inhibitory receptor structure comprising an antigen recognition domain with specificity to antigens only presented
on normal tissue, and an inhibitory signaling domain to abort T cell behavior despite concurrent engagement of an activating receptor.
In this way, the iCAR-T cell can distinguish the tumor and off-tumor cells, and reversibly restrict CAR-T cell functions in an antigen-
selective manner, such as the PD-1- and CTLA-4-based iCARs. For upper right, the modified-T cell cotransduced with a CAR, which
stimulates an activation signaling pathway upon binding to the first antigen and a chimeric costimulatory receptor (CCR) that recognizes
a second antigen to provide the costimulatory signal, can eliminate the cancer cells expressing both antigens rather than either antigen
alone. This dual receptor pattern provides a safe path to restricting the activity of engineered T cell in vitro and in vivo. For lower left
and lower middle, the split CAR-T cell with two physically separate ports exert the therapeutic functions in the presence of tumor
antigens and a heterodimerizing small molecule, AP21967. For lower right, bispecific antibodies are used as a switch to control the
interaction between the cancer cell and CAR-T cell. The lower three strategies are similar, in which the cytotoxicity of CAR-T cell are
dependent upon presence of exogenous molecule and tumor antigens
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Strategies to improve the safety and efficacy of CAR
modified-T cells
Suicide gene
A safe and efficient means of resolving these adverse
effects is the incorporation of suicide genes into the
engineered T cells. In this approach, a molecule inciting
the cells to apoptosis is administered in an adverse event
for killing the transduced-T cell with a suicide-gene prod-
uct. Based on the previous reports, there are, to date, two
types of the suicide genes that have been integrated into
CAR-T cells. Initial research into this field showed the
herpes simplex virus thymidine kinase (HSV-TK) to be
expressed in donor T cells, which has shown noticeable
function as a safety switch in clinical trials for cellular
therapies [65, 66]. The cell death caused by this suicide
strategy, however, may take a long time and remove some
of the engineered T cells resulting from the functional
mechanism related to blockage of the DNA synthesis
[67, 68]. Nevertheless, because it is derived from the
virus, HSV-TK may be immunogenic in humans [69].
Fig. 3 Combinatorial strategy for therapeutic T cell that integrates activation signaling pathway and inhibitory signaling pathway. In the promotion of
the activation signaling pathway, this design conformation of the modified-T cell can yield safer therapeutic function upon the safe platform, including
the dual receptor engineering T cell and bifunctional molecules. In this system, the T cell that carry two receptors can engage the molecules and
tumor surface antigens, and the bifunctional molecule can target T cells and cancer cells. On the other hand, blocking the inhibitory signaling pathway
by adding some monoclonal antibodies, such as tremelimumab and nivolumab with specificity for CTLA-4 and PD-1, respectively, was also found to
improve the efficacy and persistence of the infused CAR-T cell in vitro and in vivo
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With the advance in suicide-gene technology, a suicide
system based on an inducible caspase-9 (iCasp9) protein
was activated through a specific chemical molecule,
which has been shown to be safe in vivo [70]. This
“safety switch” can be inveterately and efficiently
expressed in human T lymphocytes and facilitate the
maintenance of natural phenotype and antigen specifi-
city [71–73]. In this suicide system, the suicide gene is
composed of the sequence of the FK506-binding protein
with an F36V mutation (FKBP12-F36V) that has a high
affinity to a small-molecule, AP1903, and a gene encod-
ing human caspase 9 switch (Fig. 2 upper left) [73]. Ex-
periments show that iCasp9 suicide gene can induce
approximately 99% of transduced cells apoptosis in vitro
and in vivo with a 10 nM dose of AP1903 [73]. The
iCasp9-based cell has some potential advantages over
the HSV-TK suicide gene for cellular therapy [74]. For
instance, the iCasp9 system is humanized through the
involvement of a human gene, resulting in the low po-
tential immunogenicity. Furthermore, administration of
the exogenous AP1903 has an effective and specific abil-
ity to eliminate the cell with a transgene expression ra-
ther than untransduced cells. A novel 4th generation
CD30 CAR-T cell engineered with a self-withdrawal
mechanism (FKBP-iCasp9) has shown both efficacy and
safety in lymphoma patients in clinical trial
NCT02274584. Another clinical case on iCasp9 suicide
switch, NCT02414269, the purpose of this phase I study
is to test the safety of different doses of the mesothelin-
targeted CAR-T cell in patients with malignant pleural
disease. Although this method is an important part of the
toolbox for engineering therapeutic T cells, it has several
intrinsic defects [75, 76]. The suicide switches thoroughly
abort the activity of infused cell with a complex and
expensive manufacture in an irreversible fashion. In
addition, the suicide gene in some modified cells may not
act quickly enough to eliminate the off-tumor toxicity dur-
ing initial cell transfer in vivo because the death of target
cells may take several minutes after drug administration.
Inhibitory chimeric antigen receptor
An effective strategy for the moderation of immunotoxi-
city derived from the therapeutic cells depends upon the
use of exogenous inhibitors that possess some cytostatic
or cytotoxic effects for CAR-T cells, such as corticoste-
roids [77]. However, this user control approach fails to
discriminate between beneficial and deleterious T cell
functions in some clinical trials. Additionally, exogenous
drugs may trigger several other adverse effects, especially
severe organ damage [78]. Next, the negative regulatory
receptors engineering strategies, such as PD-1 and
CTLA-4 immune inhibitor receptors, which can mitigate
the cytotoxicity responses of CAR-T cell when a specific
“protect me” ligand presented only on the healthy tissue
is recognized and captured (Fig. 2 upper middle) [79]. In
general, the inhibitory receptors can be upregulated to
regulate the number of activated T cell when the immune
responses were activated. Based on the mechanism of
immune inhibitory receptors, Fedorov et al. described an
inhibitory chimeric antigen receptor (iCAR) that can over-
ride the T cell responses, and results demonstrated that
the iCARs can specifically hinder T cell behaviors from
activation, proliferation, and cytokine secretion via the
surface TCR or CAR domain with targeting tumor
antigen [3, 79, 80].
To prevent the unwanted effects of T cell therapy, the
iCAR-engineered T cell can selectively produce cytotox-
icity only when the activating receptor comes into con-
tact with tumor antigen, and then transition to a resting
state when the inhibitory receptor is targeted with the
antigens that are only presented on normal tissues.
Notably, this method is a powerful brake for T cells
because the inhibitory receptors specifically expressed
on activated T cell are mobilized to effectively limit T
cell responses. Generally, this genetically engineered re-
ceptor regulates T cell responses in an antigen-selective
manner. However, unlike antibody-mediated checkpoint
blockade, the iCAR-T cells cannot control their spatio-
temporal activity.
Dual-antigen receptor
Another means of increasing the safety of engineered
T cell can be demonstrated upon coexpression of two
antigen receptors to target two different tumor-associated
antigens (Fig. 2 upper right) [81]. Because of the rarity of
real tumor specific antigens, to date, some engineering
strategies that can specifically identify a tumor-specific
antigen through an engineered CAR or TCR are restricted
to apply for killing tumor, especially in solid-tumor
cancers. Therefore, the dual-antigen receptor of engi-
neered T cell module has been reported to have less
intense side effects even in the absence of a truly tumor-
restricted antigen. In previous studies, two types of this
module have been characterized in combinatorial recogni-
tion manner [82, 83]. Here, we make a conclusion about
their advantages and describe the different mechanisms of
the killing pathway. First, based on the mechanism of
antigen encounter and the stage of T cell activation, the
dual pathway from the interaction between T cell and
antigen-presenting cell is required for full activation of the
T cells [84]. The first signal pathway involves tumor anti-
gen recognition through the extracellular TCR complex
and the activation signal transduction with the CD3ζ
domain. If the engineered T cells have only the first signal
upon the TCR-CD3ζ, however, the activation and
durability of T cell are usually transient, such as the first
generation of CAR-T cell. The complementary signal
pathway provided by costimulatory molecules on antigen
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presenting cells promotes the survival and expansion of
the modified-T cell. The split module of signal pathway
helps the T cell control tumor accurately as a result of the
dual targeting approach [82, 85]. In 2012, Kloss and
coworkers presented a tumor-sensing approach to suc-
cessfully redirect the T cell specificity for a tumor tissue in
the absence of a truly tumor-specific antigen. In this way,
the dual-receptor T cell can secrete cytokines and exhibit
cytotoxicity once the CAR encounters the first antigen
and a chimeric costimulatory receptor (CCR) targeting
another antigen [82]. To investigate the antitumor activity
of this engineered-T cell for prostate tumors expressing
prostate stem cell antigen (PSCA), prostate-specific mem-
brane antigen (PSMA) or both antigens in vivo, they intra-
venously injected the dual-receptor T cell showing CAR
and CCR with a specificity for PSCA and PSMA, respect-
ively, and then tested only for the robust proliferation and
tumor eradication in mice bearing the double-positive
tumors. The treatment resulted in complete long-term
survival rather than in single-positive tissues. However,
this tumor-sensing method may have a potential “on-tar-
get, off-tumor” effect due to the modified-T cell activated
by dual-target tumor can eliminate the normal tissue
expressing single tumor-associated antigen specificity
for the CAR [86].
Synthetic Notch (synNotch) receptors were developed
by Roybal et al. to serve as a general platform for gener-
ating novel cell-cell communications toward the purpose
of producing a safer and more effective dual-receptor T
cell. Results were made public in two recent reports in
Cell [83, 87]. In this system, activating T cells requires
two mechanical processes. First, the synNotch receptor
can release a transcription factor to control a CAR
expression when the T cell recognizes the first antigen,
the tissue-specific antigen. Secondly, the CAR targeting
the second antigen causes the T cell to enter a state in
which the effect cell has a high activation, proliferation,
and cytotoxicity for target cells. On account of the
SynNotch receptor to gate and confine the expression of
the CARs, it increases the landscape of targetable anti-
gens for CARs and simultaneously reduces the toxicity
derived from the use of conventional CARs [88]. This
makes this is a unique way in which the synNotch recep-
tors and CARs could improve the therapeutic ability of
T cell to identify tumor sites with a high specificity and
accuracy.
ON-switch CAR
With the advance of strategies for controlling the timing
and intensity of engineered T cells, Wu and colleagues
recently proposed a complementary positive-regulation
manner that the therapeutic cell, termed an ON-switch
CAR-T cell, can eliminate target cells bearing cognate
antigens in the presence of an exogenous molecule,
rapamycin analog AP21967 (Fig. 2 lower left) [89].
Unlike other positive regulations, this ON-switch struc-
ture can target the tumor tissue attributed to the CAR
with a specificity to tumor antigens, facilitating the grad-
ual titration of therapeutic activity to appropriate levels
by varying the concentration of the molecules, and regu-
late the timing of T cell activation through addition or
removal of the small molecule in order to mitigate some
severe toxicities. They have constructed the ON-switch
CAR with split synthetic receptor system in which the
first part of the receptor mainly contains an antigen
binding domain, scFv, and another part features two
downstream signaling elements, CD3ζ and 4-1BB. In this
way, the immunoreactivity of therapeutic cell depends
upon the tumor antigen and a small molecule.
Similar to this design, Juillerat et al. describe a method
to construct “transient” CAR-T cells with a new CAR
architecture that is directly dimerized at the hinge
domain with addition of the specific molecule (Fig. 2
lower middle) [90]. Finally, they confirmed that the
convenient-to-operate strategy mentioned in their report
can offer a basic platform to use alternative split-CARs
and show a safer way toward the development of the
engineered CAR-T cell. In summary, the type of exogen-
ous control behavior based on small molecules here re-
lates to the general principle of integrating autonomous
signals with input control. The ON-switch CAR and
transient CAR can be implemented for the modified-T
cell resulting in ultimately altering conventional T cells
into smart T cells whose therapeutic behaviors are pre-
cise and effective and subject to user control.
Bifunctional molecules as switches
With the rapid development of the bispecific antibodies
in cancer therapy, using the bifunctional molecule as a
switch to control the activity of T lymphocytes is
another exogenous approach to enhance the safety and
efficacy of infused immune cells. In the field of immune
cell therapy, the bispecific antibodies can be developed
as an efficacious bridge to recruit the cytotoxic T cells to
kill cancer cells while simultaneously targeting CD3 mole-
cules of T cell and tumor-associated antigen presented on
cancer cell surface, resulting in T cell activation and then
the destruction of the target cell (Fig. 2 lower right) [91].
This novel design may ultimately overcome some hurdles
for the safety of current CAR-T cell immunotherapy and
provide a promising approach to improve treatment ef-
fects. The results of research performed by Sun et al. show
that the anti-CD19/CD3 bispecific T cell engager (BiTE)
has had some encouraging clinical effects [92]. Then the
anti-CD20/CD3 BiTE was also constructed using “knobs-
into-holes” technique. Some efficacy studies in murine
models demonstrate that the anti-CD20/CD3 molecule
can kill B cells and show a high specificity for both
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effector and target cells even at low doses. The principal
mechanistic features of the anti-CD20/CD3 described in
their report involve broad activity against malignant B
cells with very low CD20 expression levels, and the cyto-
toxicity for target cell through the granzyme and perforin
pathway of T cell. Kim and collaborators have provided
another form of bifunctional molecule, consisting of
folate coupled with fluorescein isothiocyanate (folate-
FITC), which can redirect and regulate the activity of
the FITC-specific CAR-T cells toward tumor cells
with folate receptors (FR) [93]. In their experiment,
this switchable platform has shown a high specificity for
FR-positive cells with no activity against FR-negative cells,
which demonstrates the specific redirection of the CAR-T
cell by folate-FITC molecule. Finally, they confirmed that
the cytotoxicity of the modified-T cell is strictly dependent
on the presence of both folate-FITC molecule and
FR-positive cells, and the CAR-T cells eventually elim-
inate the target cells with this bifunctional molecule
in a concentration-dependent manner.
The latest research papers on a peptide-specific
switchable CAR-T (sCAR-T) published in PNAS have
depicted a new engineered-T system which the sCAR-T
cell, switch and target cell can assemble in a spatio-
temporal control manner [94, 95]. In vivo in case of B-cell
leukemia, the activation, tissue-homing, and cytokine re-
lease of sCAR-T cells can be controlled upon administra-
tion of small switches consisting of a peptide neo-epitope
(PNE), and a scFv specificity for target antigen, such as
PNE-CD19 and PNE-CD22. The ability of another univer-
sal CAR-T, called anti-FITC CAR-T cell, was confirmed
using the FITC-CD19 molecule or FITC-CD20 molecule
in xenograft models, resulting in potent, dose-dependent
antitumor activity, and slight toxicity. In conclusion, the
versatile strategy related to many different tumor antigens
with a single-scFv CAR-T cell should be an effective
means of surmounting the tumor escape variants and
heterogeneity, and can also simplify manufacturing of
engineered-T cells for different tumor antigens, which
greatly reduces expense [96].
Conclusions and perspectives
Through some clinical trials on the impressive activity of
the modified-T cells, such as ClinicalTrials.gov nos.
NCT01029366, NCT02030847, and NCT02388828, this
cell-based therapy has been given high expectations for
tumor eradication. Even though successful tumor eradi-
cation, this form of immunotherapy can cause some
systemic life-threatening adverse effects, such as CRS
and “on-target, off-tumor” toxicity. In some previous
reports, strategies toward amelioration of the adverse
effects derived from the CAR-T cell therapy in patients
with some serious diseases can be divided into two
categories. First, some forms of the CAR structure and
autocrime cytokines have been developed to enhance
the CAR-T cell abilities for its specific recognition and
homing. On the other hand, the timing, dose, and loca-
tion of the CAR-T cell therapy can be precisely regulated
in vitro and in vivo upon addition of some molecules
that are used as a switch and rheostat to achieve a
remote control for therapeutic T cells.
In this review, the forms of cellular control represent
autonomous control (e.g., tumor antigens), user control
(e.g., small molecules), or both. This strategy toward
improving the safety of CAR-T cell therapy involves the
use of active molecules, including dimerization molecules
and bifunctional molecules. This exogenous approach to
cellular regulation is likely to become increasingly safe
and effective, and also allows for more precise control
over the timing and location of the immune response.
With advances in the dual-receptor paradigm in the field
of cell therapy, the new mode of synthetic combinatorial
system that includes the dual-receptor CAR with the
bifunctional molecules comprising targeted molecule and
antitumor molecule may provide an important platform
for producing more controllable cellular therapeutic T
cells (Fig. 3). The switchable dual-receptor CAR-T charac-
terized above, termed sdCAR-T, may have some advan-
tages with bifunctional molecule for antitumor effect.
Firstly, the immune response of sdCAR-T cell against the
tumor tissue is dependent on the bifunctional molecule as
a switch to simultaneously redirect the tumor cell and
molecule-specific CAR-T cell. Second, the therapeutic
activity of the dual-receptor CAR-T cell can be titratable
by varying concentration of the bifunctional molecule,
resulting in precision-control of the therapeutic T cell.
Third, the durability of the CAR-T therapeutic effects is
greatly increased due to the bifunctional molecules with a
long half-life in vivo and in vitro relative to the constitu-
tive single-molecule. Finally, the overall antitumor activity
of this combinatorial system will be improved associated
with the exogenous molecule carrying the ability to
suppress tumor growth. In this way, the combinatorial
therapy, a promising pattern of the cell therapy in the war
against cancer, now raises the possibility that the tumor
cells could be killed based on autonomous tumor antigens
and active molecules. This method may have better safety
and efficacy than current CAR-T cell.
Conclusively, the cancer biotherapy, including the
adoptive immunotherapy with genetically modified T
cells and immune checkpoint blockade therapy, has
produced better antitumor response than other therap-
ies. Integration therapy involving modified-T cells and
immune checkpoint blockade may be an effective means
of ultimately eliminating tumor cells (Fig. 3). The switch-
able CAR-T cells have a controllable cytotoxicity for miti-
gating tumor burden with the bifunctional molecules.
Additionally, using monoclonal antibodies to target the
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immune checkpoints may produce more efficient T cell
behavior. In this way, this combinatorial control system
may provide a valuable insight for further refining spatio-
temporal control of CAR-T cell therapy.
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GvHD: Graft-versus-host disease; HPSE: Heparanase; HSV-TK: Herpes simplex
virus thymidine kinase; iCasp9: Inducible caspase-9; IFN-γ: Interferon γ;
IL-12: Interleukin 12; IL-6: Interleukin 6; ITAMs: Immunoreceptor tyrosine
activation motifs; MHC: Major histocompatibility complex; PD-1: Programmed
death 1; PNE: Peptide neo-epitope; PSCA: Prostate stem cell antigen;
PSMA: Prostate-specific membrane antigen; sCAR: Switchable CAR;
scFv: Single-chain antibody fragments; sdCAR: Switchable dual-receptor
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